Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Rhea-AI Summary
Illumina (NASDAQ: ILMN) appointed Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. He is Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories.
He brings experience in drug discovery, clinical development, translational medicine, and precision medicine.
Positive
- None.
Negative
- None.
News Market Reaction – ILMN
In the Jun 23 session, ILMN gained 2.20%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.4% during that session. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board
"Dan brings a rare combination of scientific expertise, innovation leadership, and healthcare impact," said Jacob Thaysen, chief executive officer of Illumina. "His experience building and advancing large research portfolios gives our Board a perspective that can help strengthen Illumina's ability to drive innovation across genomics, multiomics, and precision medicine."
Dr. Skovronsky currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, where he leads Lilly's global research and development organization and oversees commercial products across Lilly Cardiometabolic Health, Lilly Immunology, and Lilly Neuroscience.
He joined Lilly in 2010, following the acquisition of Avid Radiopharmaceuticals, a company he founded in 2004 and led as Chief Executive Officer. Since joining Lilly, he has held roles of increasing responsibility across the organization.
He previously served on the Board of Directors of Myriad Genetics, Inc.
Dr. Skovronsky received a Bachelor of Science in molecular biophysics and biochemistry from Yale University and earned both his MD and PhD from the University of
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/daniel-m-skovronsky-md-phd-appointed-to-illuminas-board-of-directors-302807233.html
SOURCE Illumina, Inc.